Fonds de solidarité FTQ puts $5.75 mln to work in Immunovaccine
Fonds de solidarité FTQ has invested $5.75 million in Immunovaccine Inc (TSX: IMV), a clinical-stage biopharmaceutical company with offices and labs in Halifax and Québec City. The investment was made through a $14.4 million bought deal offering closed last week. Founded in 2000, Immunovaccine develops cancer immunotherapies and infectious disease vaccines using DepoVax, a proprietary drug release platform. Led by President and CEO Frédéric Ors, the company will use the funds raised for R&D to further advance its product pipeline. Immunovaccine's other Canadian investors include CTI Life Sciences Fund.
20 February 2018•3 mins read
